Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDavid A. Reardonen_US
dc.contributor.authorJames E. Herndonen_US
dc.contributor.authorKatherine Petersen_US
dc.contributor.authorAnnick Desjardinsen_US
dc.contributor.authorApril Coanen_US
dc.contributor.authorEmil Louen_US
dc.contributor.authorAshley Sumrallen_US
dc.contributor.authorScott Turneren_US
dc.contributor.authorSith Sathornsumeteeen_US
dc.contributor.authorJeremy N. Richen_US
dc.contributor.authorSusan Boultonen_US
dc.contributor.authorEric S. Lippen_US
dc.contributor.authorHenry S. Friedmanen_US
dc.contributor.authorJames J. Vredenburghen_US
dc.contributor.otherDana-Farber Cancer Instituteen_US
dc.contributor.otherDuke University School of Medicineen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherCleveland Clinic Foundationen_US
dc.identifier.citationJournal of Neuro-Oncology. Vol.107, No.1 (2012), 213-221en_US
dc.description.abstractAlthough outcome following bevacizumab among recurrent grade IV malignant glioma patients is documented as poor by several analyses, outcome for recurrent grade III patients following bevacizumab therapy has not been specifically evaluated. We performed a pooled analysis of 96 recurrent grade III malignant glioma patients enrolled on three consecutive phase II bevacizumab salvage trials to evaluate overall outcome following bevacizumab trial discontinuation. Outcome on the three bevacizumab trials, which included similar eligibility, treatment and assessment criteria, was comparable. Fortynine patients who progressed on bevacizumab trial therapy and remained alive for at least 30 days elected to receive additional therapy. These patients achieved a median PFS- 6 and OS of 30.6% (95% CI: 18.4, 43.6) and 10.3 months (95% CI: 5.2, 11.7), respectively. Among patients who continued bevacizumab therapy (n = 23) after study progression, PFS-6 and median OS were 39.1% (95% CI: 19.9, 58.0) and 9.2 months (95% CI: 5.2, 13.6), respectively, compared to 23.1% (95% CI: 9.4, 40.3; P = 0.51) and 10.3 months (95% CI: 2.5, 14.4; P = 0.91) for patients who initiated non-bevacizumab containing therapy (n = 26). Outcome after discontinuation of bevacizumab therapy for recurrent grade III malignant glioma patients is associated with improved outcome compared to historical data for recurrent grade IV malignant glioma patients. Salvage therapies following bevacizumab failure have modest activity for grade III malignant glioma patients that is independent of further bevacizumab continuation. © Springer Science+Business Media, LLC. 2011.en_US
dc.rightsMahidol Universityen_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleOutcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patientsen_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.